Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2022 Jul 15;17(1):93.
doi: 10.1007/s11657-022-01124-7.

Prevalence and treatment of fragility fractures in Spanish primary care: PREFRAOS study

Daniel Martínez-Laguna  1   2 , Cristina Carbonell  3   4 , José-Carlos Bastida  5 , Milagros González  6 , Rafael M Micó-Pérez  7 , Francisco Vargas  8 , Mónica Balcells-Oliver  9 , Laura Canals  10 ; PREFRAOS Group
Affiliations
Observational Study

Prevalence and treatment of fragility fractures in Spanish primary care: PREFRAOS study

Daniel Martínez-Laguna et al. Arch Osteoporos. .

Abstract

In Spanish primary care (PC), the prevalence of fragility fractures (FF) in subjects ≥ 70 years old is high, especially in women. One-third of subjects with an FF lacked osteoporosis (OP) diagnosis and >50% were not currently receiving OP medication. An improvement of the FF management in this population is needed.

Purpose: In Spanish PC, the prevalence of FF is high, especially in women. One-third of subjects with a FF lacked an OP diagnosis and more than half were not currently receiving OP medication. Several studies reported underdiagnosis/undertreatment of OP in PC among elderly subjects with FF. To date, no such data exist for Spain. The purpose is to estimate the prevalence of FF in the elderly population (≥ 70 years old) and to describe the characteristics, risk factors, comorbidities, and OP diagnosis and treatment rates of subjects with FF in Spanish PC centers.

Methods: This is an observational, retrospective study in Spain consisting of two phases. Phase A included all subjects ≥ 70 years old listed in the center's medical records from November 2018 to March 2020. Phase B included subjects with FF and prior consultation at the center for any reason. Subjects were excluded only if they had previously participated in another study. Primary outcomes were prevalence of FF (phase A) and characteristics of subjects with at least one FF (phase B).

Results: The overall prevalence of FF was 17.7% among subjects visiting medical centers for any reason (24.1% women vs. 8.0% men) (30 PC centers from 14 Spanish regions). Vertebral (5.1%) was the most prevalent fracture. Of 665 subjects in phase B, most (87%) were women and ≥ 80 years old (57%), suffered mainly major OP fracture (68%), and had multiple comorbidities (≥ 2, 89.2%). While two-thirds had OP diagnosis and 61.1% received OP medication anytime in the past, 56.8% were not currently receiving OP medication. Diagnosis and treatment rates were lower among men (43% and 38% vs. 70% and 65%, respectively).

Conclusion: Prevalence of FF was high, especially in women. One-third of subjects lacked OP diagnosis and ≥ 50% were not receiving OP treatment; diagnosis and treatment gaps were larger among men. This reinforces the need to improve the management of FF in the elderly population. However, as PC centers participating in this study had high OP experience that have the potential to do better in terms of diagnosis and treatment, caution in the generalization of these data should be taken.

Keywords: Diagnostic; Fragility fracture; Osteoporosis; Prevalence; Primary care; Treatment.

PubMed Disclaimer

Conflict of interest statement

DML: personal fees from Amgen, Lilly, Rubió, Gedeon Richter, Pierre Fabre, Grünenthal, Theramex, and Italfarmaco; JCB: personal fees from AstraZeneca, Esteve, Boehringer Ingelheim, Bayer, Abbott, Almirall, Amgen, Chiessi, FAES, Grunenthal, GSK, Lilly, Menarini, MSD, Pfizer, Recordatti, Rovi, and Servier; MG: personal fees from Amgen, Stada, Rubió, and Grünenthal; RMP: fees from Amgen, UCB, Stada, Angelini, and Gebro; FV: personal fees from Pfizer, Grünenthal, MSD, Amgen, GSK, Lilly, Bristol-Myers Squibb, Servier, P&G Pharmaceuticals, Novartis, Almirall, Sanofi, and Mundipharma; MB and LC: Amgen employees.

Figures

Fig. 1
Fig. 1
Prevalence of fragility fractures (any type) in subjects aged ≥ 70 years (phase A)
Fig. 2
Fig. 2
Prevalence of fragility fractures at specific sites in subjects aged ≥ 70 years (phase A)
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Neustadt J (2013) Osteoporosis: beyond bone mineral density to maximize fracture reduction. Anti-Aging Therapeutics - 2012 Conference Year 121–38
    1. Harvey NCW, McCloskey EV, Mitchell PJ, Dawson-Hughes B, Pierroz DD, Reginster J-Y, et al. Mind the (treatment) gap: a global perspective on current and future strategies for prevention of fragility fractures. Osteoporos Int. 2017;28(5):1507–1529. doi: 10.1007/s00198-016-3894-y. - DOI - PMC - PubMed
    1. Kanis JA, Johnell O, Oden A, Sembo I, Redlund-Johnell I, Dawson A, et al. Long-term risk of osteoporotic fracture in Malmö. Osteoporos Int. 2000;11(8):669–674. doi: 10.1007/s001980070064. - DOI - PubMed
    1. Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster J-Y, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2013;24(1):23–57. doi: 10.1007/s00198-012-2074-y. - DOI - PMC - PubMed
    1. Bougioukli S, Κollia P, Koromila T, Varitimidis S, Hantes M, Karachalios T, et al. Failure in diagnosis and under-treatment of osteoporosis in elderly patients with fragility fractures. J Bone Miner Metab. 2018;17:37. - PubMed

Publication types